AbbVie and Alvine Pharmaceuticals have entered into a global collaboration to develop an oral treatment for celiac disease. ALV003, currently in Phase II development, is an investigational therapy composed of two recombinant, gluten-specific enzymes, and has been shown to reduce the symptoms and intestinal injury associated with celiac disease.   AbbVie will make an initial upfront payment of $70 million for an exclusive option to either acquire the ALV003 assets, or gain equity in the company. ...